| 2.525 -0.04 (-1.56%) | 05-23 09:49 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.29 | 1-year : | 3.62 |
| Resists | First : | 2.81 | Second : | 3.09 |
| Pivot price | 2.65 |
|||
| Supports | First : | 2.35 | Second : | 1.96 |
| MAs | MA(5) : | 2.59  |
MA(20) : | 2.73 |
| MA(100) : | 3.38 |
MA(250) : | 3.88 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 40.6 |
D(3) : | 40.3 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 5.07 | Low : | 2.35 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ OSUR ] has closed above bottom band by 36.2%. Bollinger Bands are 8.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.65 | 2.65 - 2.66 |
| Low: | 2.46 - 2.48 | 2.48 - 2.49 |
| Close: | 2.54 - 2.56 | 2.56 - 2.58 |
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Tue, 20 May 2025
Orasure Technologies Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing - marketscreener.com
Mon, 19 May 2025
OraSure rises as seen benefitting from 23andMe/Regeneron deal - Seeking Alpha
Mon, 19 May 2025
OraSure Technologies (OSUR) Maintains In-Line Rating with Everco - GuruFocus
Mon, 19 May 2025
OraSure Technologies (OSUR) Sees Positive Market Reaction | OSUR Stock News - GuruFocus
Fri, 09 May 2025
OraSure Technologies, Inc. (NASDAQ:OSUR) Q1 2025 Earnings Call Transcript - Insider Monkey
Thu, 08 May 2025
Shareholders Will Probably Hold Off On Increasing OraSure Technologies, Inc.'s (NASDAQ:OSUR) CEO Compensation For The Time Being - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 77 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 4 (%) |
| Held by Institutions | 98.7 (%) |
| Shares Short | 2,120 (K) |
| Shares Short P.Month | 2,140 (K) |
| EPS | -0.26 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.28 |
| Profit Margin | -19.8 % |
| Operating Margin | -61.1 % |
| Return on Assets (ttm) | -4.9 % |
| Return on Equity (ttm) | -7.8 % |
| Qtrly Rev. Growth | -44.8 % |
| Gross Profit (p.s.) | 0.88 |
| Sales Per Share | 2.08 |
| EBITDA (p.s.) | -0.32 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 12 (M) |
| PE Ratio | -9.87 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 1.22 |
| Price to Cash Flow | 220.35 |
| Dividend | 1.6 |
| Forward Dividend | 0 |
| Dividend Yield | 62.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|